NEPTUNE

What do patients gain by participating in clinical trials?

• Actively participate in their health care
• Obtain access to new treatments before they are widely accessible
• Help others by contributing to the progression of medical research

Before the FDA can approve a therapy, 3 phases of study must be successfully completed:

Phase 1: The treatment is administered to a small group of people (about 20-80) to assess the safety, determine a dosage range, and detect any possible side effects.

Phase 2: A larger group of about 100-300 people receive the treatment to examine its effectiveness and further assess its safety.

Phase 3: The treatment is administered to an even larger group of 1,000- 3,000 to verify its usefulness, monitor side effects, compare it to existing treatments, and obtain more information to insure that the treatment is used safely.

For a list of nephrotic syndrome-specific clinical trials, please click here

To learn more about Nephrotic Syndrome, please click here.

Newest postings:

PROMIS: Nephrotic Syndrome Study

Childhood onset nephrotic syndrome occurs when the kidneys leak large amounts of protein into the urine. Nephrotic syndrome is a disease that can be persistent, improve (remission) or cycle between remission and active (relapse) periods. The purpose of this study is to learn how your child feels when he or she has active nephrotic syndrome as compared to when he or she is in remission. Your child will complete an internet based survey at 3 different times in a single year. The survey will ask how he or she feels during daily activities at home and at school.

To take part in this study your child must have nephrotic syndrome and be between 8 and 17 years old. He or she needs to be able to read English. Enroll in this study here: PROMIS

Clinical Trial for Membranous Nephropathy Patients:

A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)

Eligibility for Study: Men & Women ages 18 years to 75 years with a history of nephrotic syndrome due to idiopathic Membranous Nephropathy as confirmed by documented result from a renal biopsy.

Click here for more information and complete list of inclusion and exclusion criteria.